EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer—2020 update. Part 1: screening, diagnosis, and local treatment with curative intent

N Mottet, RCN van den Bergh, E Briers… - European urology, 2021 - Elsevier
Objective To present a summary of the 2020 version of the European Association of Urology
(EAU)-European Association of Nuclear Medicine (EANM)-European Society for …

Radiation therapy‐associated toxicity: Etiology, management, and prevention

K Wang, JE Tepper - CA: a cancer journal for clinicians, 2021 - Wiley Online Library
Radiation therapy (RT) is a curative treatment for many malignancies and provides effective
palliation in patients with tumor‐related symptoms. However, the biophysical effects of RT …

Magnetic resonance imaging–guided vs computed tomography–guided stereotactic body radiotherapy for prostate cancer: the MIRAGE randomized clinical trial

AU Kishan, TM Ma, JM Lamb, M Casado… - JAMA …, 2023 - jamanetwork.com
Importance Magnetic resonance imaging (MRI) guidance offers multiple theoretical
advantages in the context of stereotactic body radiotherapy (SBRT) for prostate cancer …

EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II—2020 update: treatment of relapsing and metastatic prostate cancer

P Cornford, RCN van den Bergh, E Briers… - European urology, 2021 - Elsevier
Objective To present a summary of the 2020 version of the European Association of Urology
(EAU)-European Association of Nuclear Medicine (EANM)-European Society for …

Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international …

DH Brand, AC Tree, P Ostler, H van der Voet… - The Lancet …, 2019 - thelancet.com
Background Localised prostate cancer is commonly treated with external-beam
radiotherapy. Moderate hypofractionation has been shown to be non-inferior to conventional …

Screening for prostate cancer: US Preventive Services Task Force recommendation statement

DC Grossman, SJ Curry, DK Owens… - Jama, 2018 - jamanetwork.com
Importance In the United States, the lifetime risk of being diagnosed with prostate cancer is
approximately 11%, and the lifetime risk of dying of prostate cancer is 2.5%. The median age …

Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis

D Ilic, M Djulbegovic, JH Jung, EC Hwang, Q Zhou… - bmj, 2018 - bmj.com
Objective To investigate the efficacy and safety of prostate-specific antigen (PSA) testing to
screen for prostate cancer. Design Systematic review and meta-analysis. Data sources …

Prostate MRI, with or without MRI‐targeted biopsy, and systematic biopsy for detecting prostate cancer

FJH Drost, DF Osses, D Nieboer… - Cochrane Database …, 2019 - cochranelibrary.com
Background Multiparametric magnetic resonance imaging (MRI), with or without MRI‐
targeted biopsy, is an alternative test to systematic transrectal ultrasonography‐guided …

10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer

FC Hamdy, JL Donovan, JA Lane… - … England Journal of …, 2016 - Mass Medical Soc
Background The comparative effectiveness of treatments for prostate cancer that is detected
by prostate-specific antigen (PSA) testing remains uncertain. Methods We compared active …

The diagnosis and treatment of prostate cancer: a review

MS Litwin, HJ Tan - Jama, 2017 - jamanetwork.com
Importance Prostate cancer is the most common cancer diagnosis made in men with more
than 160 000 new cases each year in the United States. Although it often has an indolent …